Analysis of potential biomarkers showed reduction of CD14+ monocytes in peripheral blood suggesting a PD effect of RG7356; one of the proposed modes of action is to trigger direct antitumor effects by activating CD68+ macrophages via Fc/FcgR interaction to phagocytose CD44-positive tumor cells. Here, FCGR2A is linked to neoplasm.